265 related articles for article (PubMed ID: 14566825)
1. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
[TBL] [Abstract][Full Text] [Related]
2. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
[TBL] [Abstract][Full Text] [Related]
3. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y
Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
5. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
[TBL] [Abstract][Full Text] [Related]
6. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.
Kage K; Fujita T; Sugimoto Y
Cancer Sci; 2005 Dec; 96(12):866-72. PubMed ID: 16367905
[TBL] [Abstract][Full Text] [Related]
7. [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].
Yuan JH; He ZM; Yu YH; Chen ZC
Ai Zheng; 2004 Oct; 23(10):1127-33. PubMed ID: 15473921
[TBL] [Abstract][Full Text] [Related]
8. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q
J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106
[TBL] [Abstract][Full Text] [Related]
9. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
10. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.
Kage K; Tsukahara S; Sugiyama T; Asada S; Ishikawa E; Tsuruo T; Sugimoto Y
Int J Cancer; 2002 Feb; 97(5):626-30. PubMed ID: 11807788
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
12. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
14. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Kawabata S; Oka M; Shiozawa K; Tsukamoto K; Nakatomi K; Soda H; Fukuda M; Ikegami Y; Sugahara K; Yamada Y; Kamihira S; Doyle LA; Ross DD; Kohno S
Biochem Biophys Res Commun; 2001 Feb; 280(5):1216-23. PubMed ID: 11162657
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
19. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Minderman H; O'Loughlin KL; Pendyala L; Baer MR
Clin Cancer Res; 2004 Mar; 10(5):1826-34. PubMed ID: 15014037
[TBL] [Abstract][Full Text] [Related]
20. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
Yanase K; Tsukahara S; Mitsuhashi J; Sugimoto Y
Cancer Lett; 2006 Mar; 234(1):73-80. PubMed ID: 16303243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
